SAN FRANCISCO, Dec. 4, 2018 (BUSINESS WIRE) – Cofactor Genomics, a clinical RNA sequencing and translational assay developer, today announced a pilot study to evaluate use of Cofactor’s [...]

Register for the event on December 13, 2018: Immunotherapies show promise in the treatment of oncology patients with solid tumors, but complex heterogeneity of the tumor microenvironment makes [...]

SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) — Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the launch of a RNA-based immune profiling [...]

SAN FRANCISCO, Oct. 02, 2018 (GLOBE NEWSWIRE) —  Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today that its laboratory has successfully [...]

Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the commercial launch of Paragon, a solid tumor immune-profiling assay requiring only two FFPE [...]

SAN FRANCISCO, Feb. 08, 2018 (GLOBE NEWSWIRE) — Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the commercial launch of Paragon, a solid [...]

During Natalie LaFranzo’s first days on campus as a doctoral student in chemistry, she sat in on an orientation session where a presenter stressed the need for students to stay focused, nearly [...]

SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today that results from a collaborative study with the Fred [...]

On today’s podcast, Cofactor Genomics COO, Dr. David Messina discusses how his company is working to make personalized medicine a reality by focusing on the potential of RNA as a diagnostic tool. [...]

According to Jarret Glasscock, a computational biologist and the founder and CEO of Cofactor Genomics, “Almost 95 percent of the diseases we suffer from cannot be diagnosed by DNA [...]